English
 
Help Privacy Policy Disclaimer
  Advanced SearchBrowse

Item

ITEM ACTIONSEXPORT

Released

Journal Article

Synthesis of an organoinsulin molecule that can be activated by antibody catalysis

MPS-Authors
There are no MPG-Authors in the publication available
External Resource
No external resources are shared
Fulltext (restricted access)
There are currently no full texts shared for your IP range.
Fulltext (public)
There are no public fulltexts stored in PuRe
Supplementary Material (public)
There is no public supplementary material available
Citation

Worrall, D. S., McDunn, J. E., List, B., Reichart, D., Hevener, A., Gustafson, T., et al. (2001). Synthesis of an organoinsulin molecule that can be activated by antibody catalysis. Proceedings of the National Academy of Sciences of the United States of America, 98(24), 13514-13518. doi:10.1073/pnas.241516698.


Cite as: https://hdl.handle.net/11858/00-001M-0000-0014-A4D1-F
Abstract
We have developed a methodology of prodrug delivery by using a modified insulin species whose biological activity potentially can be regulated in vivo. Native insulin was derivatized with aldol-terminated chemical modifications that can be selectively removed by the catalytic aldolase antibody 38C2 under physiologic conditions. The derivatized organoinsulin (insulinD) was defective with respect to receptor binding and stimulation of glucose transport. The affinity of insulinD for the insulin receptor was reduced by 90% in binding studies using intact cells. The ability of insulinD to stimulate glucose transport was reduced by 96% in 3T3-L1 adipocytes and by 55% in conscious rats. Incubation of insulinD with the catalytic aldolase antibody 38C2 cleaved all of the aldol-terminated modifications, restoring native insulin. Treatment of insulinD with 38C2 also restored insulinD's receptor binding and glucose transport-stimulating activities in vitro, as well as its ability to lower glucose levels in animals in vivo. We propose that these results are the foundation for an in vivo regulated system of insulin activation using the prohormone insulinD and catalytic antibody 38C2 with potential therapeutic application.